Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Limosilactobacillus reuteri - BioGaia/Infant Bacterial Therapeutics

Drug Profile

Limosilactobacillus reuteri - BioGaia/Infant Bacterial Therapeutics

Alternative Names: Apylori Probiotic Capsules; BioGaia ProTectis; IBP 9414; Lactobacillus reuteri; Lactobacillus reuteri ATCC 55730; Lactobacillus reuteri DSM 17938; Lactobacillus reuteri Protectis; NEC therapy - BioGaia

Latest Information Update: 19 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioGaia; Infant Bacterial Therapeutics
  • Class Anti-inflammatories; Antihyperglycaemics; Bacteria; Laxatives; Probiotics
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Necrotising enterocolitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastrointestinal disorders
  • Phase III Necrotising enterocolitis
  • Phase II Constipation; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jun 2023 European Patent Office approves patent application for Lactobacillus reuteri related to IBP 9414
  • 16 Jun 2023 Infant Bacterial Therapeutics plans to launch IBP 9414 in Europe
  • 22 Mar 2023 Infant Bacterial Therapeutics announces intention to submit market approval for Lactobacillus reuteri for necrotising enterocolitis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top